JP2001526269A5 - - Google Patents

Download PDF

Info

Publication number
JP2001526269A5
JP2001526269A5 JP2000525392A JP2000525392A JP2001526269A5 JP 2001526269 A5 JP2001526269 A5 JP 2001526269A5 JP 2000525392 A JP2000525392 A JP 2000525392A JP 2000525392 A JP2000525392 A JP 2000525392A JP 2001526269 A5 JP2001526269 A5 JP 2001526269A5
Authority
JP
Japan
Prior art keywords
substituted
group
alkyl
twenty
perhalo substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000525392A
Other languages
English (en)
Japanese (ja)
Other versions
JP4395823B2 (ja
JP2001526269A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1998/026082 external-priority patent/WO1999032455A1/en
Publication of JP2001526269A publication Critical patent/JP2001526269A/ja
Publication of JP2001526269A5 publication Critical patent/JP2001526269A5/ja
Application granted granted Critical
Publication of JP4395823B2 publication Critical patent/JP4395823B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2000525392A 1997-12-22 1998-12-22 アリール及びヘテロアリール置換複素環式尿素を用いたrafキナーゼの阻害 Expired - Fee Related JP4395823B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99618197A 1997-12-22 1997-12-22
US08/996,181 1997-12-22
PCT/US1998/026082 WO1999032455A1 (en) 1997-12-22 1998-12-22 Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas

Publications (3)

Publication Number Publication Date
JP2001526269A JP2001526269A (ja) 2001-12-18
JP2001526269A5 true JP2001526269A5 (US20040106767A1-20040603-C00005.png) 2006-01-05
JP4395823B2 JP4395823B2 (ja) 2010-01-13

Family

ID=25542594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000525392A Expired - Fee Related JP4395823B2 (ja) 1997-12-22 1998-12-22 アリール及びヘテロアリール置換複素環式尿素を用いたrafキナーゼの阻害

Country Status (29)

Country Link
EP (1) EP1056725B1 (US20040106767A1-20040603-C00005.png)
JP (1) JP4395823B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR100622138B1 (US20040106767A1-20040603-C00005.png)
CN (1) CN1117081C (US20040106767A1-20040603-C00005.png)
AT (1) ATE328873T1 (US20040106767A1-20040603-C00005.png)
AU (1) AU765412B2 (US20040106767A1-20040603-C00005.png)
BG (1) BG65207B1 (US20040106767A1-20040603-C00005.png)
BR (1) BR9814361A (US20040106767A1-20040603-C00005.png)
CA (1) CA2315713C (US20040106767A1-20040603-C00005.png)
CU (1) CU23127A3 (US20040106767A1-20040603-C00005.png)
CY (1) CY1105395T1 (US20040106767A1-20040603-C00005.png)
CZ (1) CZ299836B6 (US20040106767A1-20040603-C00005.png)
DE (2) DE69834842T2 (US20040106767A1-20040603-C00005.png)
DK (1) DK1056725T3 (US20040106767A1-20040603-C00005.png)
ES (1) ES2155045T3 (US20040106767A1-20040603-C00005.png)
GR (1) GR20010300010T1 (US20040106767A1-20040603-C00005.png)
HK (1) HK1029989A1 (US20040106767A1-20040603-C00005.png)
HU (1) HUP0004426A3 (US20040106767A1-20040603-C00005.png)
ID (1) ID26328A (US20040106767A1-20040603-C00005.png)
IL (2) IL136773A0 (US20040106767A1-20040603-C00005.png)
NO (1) NO319209B1 (US20040106767A1-20040603-C00005.png)
NZ (1) NZ505845A (US20040106767A1-20040603-C00005.png)
PL (1) PL341356A1 (US20040106767A1-20040603-C00005.png)
PT (1) PT1056725E (US20040106767A1-20040603-C00005.png)
RU (1) RU2265597C2 (US20040106767A1-20040603-C00005.png)
SK (1) SK285371B6 (US20040106767A1-20040603-C00005.png)
TR (3) TR200002617T2 (US20040106767A1-20040603-C00005.png)
UA (1) UA67763C2 (US20040106767A1-20040603-C00005.png)
WO (1) WO1999032455A1 (US20040106767A1-20040603-C00005.png)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1473292A1 (en) * 1997-11-03 2004-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ATE300299T1 (de) * 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
ES2155817T3 (es) * 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.
AU2006201959B2 (en) * 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
EP1041982B1 (en) * 1997-12-22 2011-10-19 Bayer HealthCare LLC INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
EP1157026A1 (en) 1999-02-22 2001-11-28 Boehringer Ingelheim Pharmaceuticals Inc. Polycyclo heterocyclic derivatives as antiinflammatory agents
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
KR100709497B1 (ko) 1999-03-12 2007-04-20 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 소염제로서 유용한 화합물 및 이의 제조방법
JP2002539206A (ja) 1999-03-12 2002-11-19 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 抗炎症剤としての芳香族複素環化合物
DE60024830T2 (de) 1999-07-09 2006-06-14 Boehringer Ingelheim Pharma Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
AP2002002442A0 (en) * 1999-08-12 2002-03-31 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents.
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
TR200201364T2 (tr) * 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
US6525046B1 (en) 2000-01-18 2003-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as antiinflammatory agents
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
AU2001287654B2 (en) * 2000-08-10 2006-12-14 Pfizer Italia S.R.I. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US6645990B2 (en) 2000-08-15 2003-11-11 Amgen Inc. Thiazolyl urea compounds and methods of uses
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
CA2445003A1 (en) 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Diarylurea derivatives useful as anti-inflammatory agents
WO2002096876A1 (en) 2001-05-25 2002-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Carbamate and oxamide compounds as inhibitors of cytokine production
EP1709965A3 (en) * 2001-07-11 2006-12-27 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating cytokine mediate diseases
ES2309207T3 (es) * 2001-09-05 2008-12-16 Smithkline Beecham Plc Derivados furanicos sustituidos con piridina como inhibidores de quinasa raf.
SI1450799T1 (sl) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
ATE386030T1 (de) 2002-02-25 2008-03-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen
JP2005537290A (ja) * 2002-07-25 2005-12-08 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤として活性なビシクロピラゾール類、その製造方法、およびそれを含有する薬学的組成物
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
CA2516931C (en) 2003-02-28 2014-09-09 Bayer Pharmaceuticals Corporation Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
CA2526285A1 (en) 2003-05-15 2004-12-23 Arqule, Inc. Inhibitors of p38 and methods of using the same
JP4860474B2 (ja) 2003-05-20 2012-01-25 バイエル、ファーマシューテイカルズ、コーポレイション Pdgfrによって仲介される病気のためのジアリール尿素
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US20050148605A1 (en) * 2003-11-13 2005-07-07 Ambit Biosciences Corporation Amide derivatives as ABL modulators
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1730129B1 (en) * 2004-03-19 2011-01-19 Dipharma Francis S.r.l. Intermediates for the preparation of pramipexole
WO2005110994A2 (en) 2004-04-30 2005-11-24 Bayer Pharmaceuticals Corporation Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7829560B2 (en) 2004-07-08 2010-11-09 Arqule, Inc. 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
EP1809636A1 (en) 2004-10-19 2007-07-25 Arqule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
AU2005321946B2 (en) * 2004-12-23 2012-08-16 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
GB0500435D0 (en) * 2005-01-10 2005-02-16 Novartis Ag Organic compounds
UA93673C2 (ru) 2005-03-07 2011-03-10 Баер Шеринг Фарма Акциенгезельшафт Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
JP5072595B2 (ja) 2005-08-05 2012-11-14 中外製薬株式会社 マルチキナーゼ阻害剤
DE102005037499A1 (de) 2005-08-09 2007-02-15 Merck Patent Gmbh Pyrazolderivate
CA2629468A1 (en) * 2005-11-15 2007-05-24 Bayer Pharmaceuticals Corporation Pyrazolyl urea derivatives useful in the treatment of cancer
US8580798B2 (en) 2005-12-21 2013-11-12 Bayer Intellectual Property Gmbh Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
EP2338488A1 (en) 2006-05-26 2011-06-29 Bayer HealthCare, LLC Drug combinations with substituted diaryl ureas for the treatment of cancer
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
CA2672951A1 (en) 2006-12-20 2008-07-03 Bayer Healthcare Llc Hydroxy methyl phenyl pyrazolyl urea compound useful in the treatment of cancer
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP5396379B2 (ja) 2007-04-02 2014-01-22 エボテック・アーゲー ピリド−2−イル縮合複素環式化合物ならびにその組成物および使用
EP2146718A4 (en) 2007-04-20 2010-08-11 Deciphera Pharmaceuticals Llc KINASEHEMMER FOR THE TREATMENT OF MYELOPROLIFERATIVE AND OTHER PROLIFERATIVE DISEASES
CL2009000448A1 (es) 2008-02-29 2009-11-27 Genentech Inc Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros.
CN102015707A (zh) 2008-02-29 2011-04-13 阵列生物制药公司 Raf抑制剂化合物及其使用方法
GB0818033D0 (en) 2008-10-02 2008-11-05 Respivert Ltd Novel compound
WO2010038086A2 (en) 2008-10-02 2010-04-08 Respivert Limited Novel compounds
CN102333770B (zh) 2008-12-11 2015-01-28 瑞斯比维特有限公司 P38map激酶抑制剂
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
EP2556067B1 (en) 2010-04-08 2016-02-24 Respivert Limited Pyrazolyl ureas as p38 map kinase inhibitors
CN103003262A (zh) 2010-07-16 2013-03-27 协和发酵麒麟株式会社 含氮芳香族杂环衍生物
WO2012012404A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP2578582A1 (en) 2011-10-03 2013-04-10 Respivert Limited 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
BR112014007694B1 (pt) 2011-10-03 2022-09-27 Respivert Limited Compostos de 1-(3-(tert-butil)-1-(p-tolil)-1h-pirazol-5-il)-3-(4-((2-(fenilamino) pirimidin-4-il)óxi) naftalen-1-il)ureia, seus usos, composição e formulação farmacêutica compreendendo os mesmos
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
KR20140011780A (ko) * 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
GB201214750D0 (en) 2012-08-17 2012-10-03 Respivert Ltd Compounds
GB201215357D0 (en) 2012-08-29 2012-10-10 Respivert Ltd Compounds
US20160016934A1 (en) 2013-03-14 2016-01-21 Respivert Limited Kinase inhibitors
US9750723B2 (en) 2013-10-31 2017-09-05 Ohio University Prevention and treatment of non-alcoholic fatty liver disease
TWI751099B (zh) 2014-02-14 2022-01-01 英商瑞斯比維特有限公司 作為激酶抑制劑之吡唑基脲,包含其之製藥組成物及其用途
US20170202818A1 (en) 2014-07-18 2017-07-20 Ohio University Methods and compositions to modify gsk-3 activity
SG11202007198WA (en) 2018-01-31 2020-08-28 Deciphera Pharmaceuticals Llc Combination therapy for the treatment of gastrointestinal stromal tumors
PT3762368T (pt) 2018-03-08 2022-05-06 Incyte Corp Compostos de aminopirazina diol como inibidores de pi3k-y
CN108484587A (zh) * 2018-06-03 2018-09-04 刘思良 一种Raf激酶抑制剂及其在癌症治疗中的应用
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
KR20220123058A (ko) 2019-12-30 2022-09-05 데시페라 파마슈티칼스, 엘엘씨. 1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of amorphous kinase inhibitors and methods of using them
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162360A (en) * 1991-06-24 1992-11-10 Warner-Lambert Company 2-heteroatom containing urea and thiourea ACAT inhibitors
GB9302275D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
GB9623833D0 (en) * 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
JP2002500650A (ja) * 1997-05-23 2002-01-08 バイエル、コーポレイション Rafキナーゼ阻害剤
WO1999023091A1 (en) * 1997-11-03 1999-05-14 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
ES2155817T3 (es) * 1997-12-22 2007-06-16 Bayer Pharmaceuticals Corp. Inhibicion de la actividad de la quinasa p38 utilizando ureas heterociclicas sustituidas con arilo y heteroarilo.

Similar Documents

Publication Publication Date Title
JP2001526269A5 (US20040106767A1-20040603-C00005.png)
RU2000120162A (ru) Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ лечения заболевания, опосредованного киназой raf, фармацевтическая композиция
JP2001526222A5 (US20040106767A1-20040603-C00005.png)
BR0010366A (pt) Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia
KR920009796A (ko) 3-아미도인돌릴 유도체
JP2003518060A5 (US20040106767A1-20040603-C00005.png)
JP2005534669A5 (US20040106767A1-20040603-C00005.png)
CA2315713A1 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
KR940005566A (ko) 퀴놀린 화합물
JP2010536887A5 (US20040106767A1-20040603-C00005.png)
DE69110320D1 (de) Stickstoff enthaltende heterozyklische Verbindungen, ihre Herstellung und Verwendung.
CA2373653A1 (en) New use of compounds as antibacterial agents
JP2005535586A5 (US20040106767A1-20040603-C00005.png)
ATE79376T1 (de) Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JP2015504067A5 (US20040106767A1-20040603-C00005.png)
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
JP2006501201A5 (US20040106767A1-20040603-C00005.png)
JP2004517843A5 (US20040106767A1-20040603-C00005.png)
EP0397040A3 (en) N-heteroaryl-4-quinolinamines, a process for their preparation and their use as medicaments
KR960007565A (ko) 약제로서의 치환된 4-페닐-6-아미노-니코틴산 유도체의 용도
CA2382247A1 (en) Azaindoles having serotonin receptor affinity
JP2006528667A5 (US20040106767A1-20040603-C00005.png)
JP2003513066A5 (US20040106767A1-20040603-C00005.png)
JP2003513075A5 (US20040106767A1-20040603-C00005.png)
RU2004122427A (ru) Пирролидин-2-оны в качестве ингибиторов фактора ха